61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial

Abstract Background An acute course of dTMS typically involves treatments delivered 5 days a week, for 4 weeks. Should more treatments be given if the patient has not responded? Data are needed to inform decisions about the best next steps for acute non-responders. Objective To characterize response...

Full description

Saved in:
Bibliographic Details
Published in:Brain stimulation 2017-07, Vol.10 (4), p.847-849
Main Authors: Yip, Agustin G, George, Mark S, Tendler, Aron, Roth, Yiftach, Zangen, Abraham, Carpenter, Linda L
Format: Article
Language:English
Subjects:
Adult
Clinical research
Depressive Disorder, Treatment-Resistant - therapy
Double-Blind Method
Female
Humans
Male
Middle Aged
Neurology
Randomized clinical trial
Transcranial magnetic stimulation
Transcranial Magnetic Stimulation - adverse effects
Transcranial Magnetic Stimulation - methods
Treatment-resistant depression
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background An acute course of dTMS typically involves treatments delivered 5 days a week, for 4 weeks. Should more treatments be given if the patient has not responded? Data are needed to inform decisions about the best next steps for acute non-responders. Objective To characterize response among acute-phase non-responders in a randomized controlled trial of deep repetitive transcranial magnetic stimulation (dTMS) monotherapy for medication-resistant depression. Methods Summary statistics and Kaplan-Meier curves were used to characterize outcomes of 33 medication-free Brainsway™ dTMS non-responders to double blind but active treatment at the end of 4 weeks (20 sessions), who then continued double blind but active twice–weekly treatment for up to 12 additional weeks. Results 24 participants (72.7%) achieved responder status during at least one rating with dTMS continuation -- 20 (60.6%) within four weeks, with 13 (39.4%) consistently meeting response criteria for the duration of the study. 20 (63.6%) achieved remission status at some point during treatment continuation. Conclusions A significant proportion of acute course non-responders to dTMS treatment eventually respond with continued treatment. Continuing TMS treatment beyond the acute course for non-responders may result in eventual response in over half of these individuals.
ISSN:1935-861X
1876-4754
DOI:10.1016/j.brs.2017.02.013